PT1344533E - Composições farmacêuticas compreendendo lectina de ligação a manose - Google Patents

Composições farmacêuticas compreendendo lectina de ligação a manose Download PDF

Info

Publication number
PT1344533E
PT1344533E PT03388016T PT03388016T PT1344533E PT 1344533 E PT1344533 E PT 1344533E PT 03388016 T PT03388016 T PT 03388016T PT 03388016 T PT03388016 T PT 03388016T PT 1344533 E PT1344533 E PT 1344533E
Authority
PT
Portugal
Prior art keywords
mbl
composition
gly
leu
ser
Prior art date
Application number
PT03388016T
Other languages
English (en)
Portuguese (pt)
Inventor
Jesper Lund Larsen
Leif Kongerslev
Original Assignee
Natimmune As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natimmune As filed Critical Natimmune As
Publication of PT1344533E publication Critical patent/PT1344533E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT03388016T 2002-03-15 2003-03-14 Composições farmacêuticas compreendendo lectina de ligação a manose PT1344533E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15

Publications (1)

Publication Number Publication Date
PT1344533E true PT1344533E (pt) 2007-01-31

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03388016T PT1344533E (pt) 2002-03-15 2003-03-14 Composições farmacêuticas compreendendo lectina de ligação a manose

Country Status (11)

Country Link
US (1) US7462596B2 (enExample)
EP (1) EP1344533B1 (enExample)
JP (1) JP2005526084A (enExample)
CN (1) CN1652813A (enExample)
AT (1) ATE337014T1 (enExample)
AU (1) AU2003215524A1 (enExample)
DE (1) DE60307701T2 (enExample)
DK (1) DK1344533T3 (enExample)
ES (1) ES2271515T3 (enExample)
PT (1) PT1344533E (enExample)
WO (1) WO2003077937A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
KR101340354B1 (ko) 2004-11-12 2013-12-11 노보 노르디스크 에이/에스 안정한 펩티드 제제
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US20080214435A1 (en) * 2005-04-11 2008-09-04 Natlmmune A/S Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
CN105963289B (zh) 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2454281B1 (en) 2009-07-17 2018-11-14 Omeros Corporation Masp isoforms as inhibitors of complement activation
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
ES2864857T3 (es) * 2012-06-18 2021-10-14 Omeros Corp Composiciones y métodos para la inhibición de MASP-1 y/o MASP-2 y/o MASP-3 para el tratamiento de diversas enfermedades y trastornos
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
EP3010522B1 (en) 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー, インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP2024537924A (ja) * 2021-10-01 2024-10-16 インスティテュート オブ ケミストリー、テクノロジー アンド メタラジー サバリア・サバグリアの炭水化物結合ポリペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334696C (en) * 1998-06-10 2014-03-25 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
RU2292217C2 (ru) * 1999-05-14 2007-01-27 Стеффен ТИЭЛЬ Рекомбинантный маннан-связывающий лектин человека
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
DE60307701T2 (de) 2007-10-11
WO2003077937A1 (en) 2003-09-25
DK1344533T3 (da) 2007-01-08
ATE337014T1 (de) 2006-09-15
US7462596B2 (en) 2008-12-09
DE60307701D1 (de) 2006-10-05
AU2003215524A1 (en) 2003-09-29
JP2005526084A (ja) 2005-09-02
EP1344533B1 (en) 2006-08-23
US20040006009A1 (en) 2004-01-08
EP1344533A1 (en) 2003-09-17
ES2271515T3 (es) 2007-04-16
CN1652813A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
PT1344533E (pt) Composições farmacêuticas compreendendo lectina de ligação a manose
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ix処方
US9968662B2 (en) Factor VII composition
BRPI0821474B1 (pt) Formulação farmacêutica líquida estável
KR20050013148A (ko) 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
CA3054718A1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
JP2010513462A (ja) 第VIIおよび第VIIa因子組成物
US20190231855A1 (en) Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders
JP2007513881A (ja) Xi因子の治療学的使用
JP6516855B2 (ja) C1エステラーゼ阻害剤の医薬製剤
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
US20240199703A1 (en) Procoagulant peptides and use thereof
EP4028046B1 (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
HK40077326A (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
HK40077326B (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
MXPA06005477A (en) Therapeutic use of factor xi